Prescient Therapeutics (ASX:PTX) completed the first site initiation visit of its phase 2a clinical study of cancer treatment candidate PTX-100, according to a Wednesday filing with the Australian bourse.
The primary endpoint of the study is efficacy, while secondary endpoints include safety, according to the filing.
The study will evaluate two dosage levels of PTX-100 in about 40 patients with relapsed/refractory cutaneous T-cell lymphoma on an open-label basis, the filing said.
Cutaneous T-cell lymphoma is a rare type of non-Hodgkin lymphoma that affects the skin.
Shares rose nearly 7% in afternoon trade Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。